Global Epinephrine Auto-Injectors Market Research Report 2022

Epinephrine auto-injector is an emergency injection ("shot") of epinephrine. It is used against life-threatening allergic reactions such as severe swelling, breathing problems, or loss of blood pressure. This medication is used in emergencies to treat very serious allergic reactions to insect stings/bites, foods, drugs, or other substances. Epinephrine acts quickly to improve breathing, stimulate the heart, raise a dropping blood pressure, reverse hives, and reduce swelling of the face, lips, and throat.
Due to the COVID-19 pandemic, the global Epinephrine Auto-Injectors market size is estimated to be worth US$ 1248.5 million in 2021 and is forecast to a readjusted size of US$ 1839.8 million by 2028 with a CAGR of 5.2% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Epinephrine Auto-Injectors market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Epinephrine Auto-Injectors landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Global core Epinephrine Auto-Injectors manufacturers include Viatris, Teva Pharmaceutica etc. The top 1 company hold a share about 42%. North America is the largest market, with a share about 75%, followed by Europe which shares about 20%. In terms of product, 0.3 mg is the largest segment, with a share about 80%. And in terms of application, the largest end user is over 12 years patients.
This report focuses on Epinephrine Auto-Injectors volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Epinephrine Auto-Injectors market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe and Israel, etc.
Global Epinephrine Auto-Injectors Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by End User. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
0.3 mg
0.15 mg
0.5 mg
0.1 mg
Segment by End User
Under 6 Years Patients
6 to 12 Years Patients
Over 12 Years Patients
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Viatris
Teva Pharmaceutica
ALK Abello
Amneal Pharmaceuticals
Kaléo
Bioprojet Pharma
Bausch Health
Novartis Sandoz